Lupin launches generic Vigamox Ophthalmic solution in US market
Mumbai, Jul 05 (UNI) Pharma major, Lupin Limited said that it has launched generic version of Moxifloxacin Hydrochloride Ophthalmic solution USP, 0.5 percentin the US market, Lupin’s Moxifloxacin Hydrochloride Ophthalmic solution USP, 0.5 percent (base), is an AT1 rated generic equivalent of Novartis Pharma Corp’s Vigamox Ophthalmic solution. Moxifloxacin Hydrochloride Ophthalmic solution is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the organisms.Vigamox Ophthalmic solution had US sales of USD 267.9 million (IMS MAT March 2017). UNI JS AW1525